ACELRX PHARMACEUT. DL-01 (R5XA) - Total Assets
Based on the latest financial reports, ACELRX PHARMACEUT. DL-01 (R5XA) holds total assets worth €29.72 Million EUR (≈ $34.74 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is ACELRX PHARMACEUT. DL-01's book value for net asset value and shareholders' equity analysis.
ACELRX PHARMACEUT. DL-01 - Total Assets Trend (2021–2025)
This chart illustrates how ACELRX PHARMACEUT. DL-01's total assets have evolved over time, based on quarterly financial data.
ACELRX PHARMACEUT. DL-01 - Asset Composition Analysis
Current Asset Composition (December 2025)
ACELRX PHARMACEUT. DL-01's total assets of €29.72 Million consist of 70.3% current assets and 29.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 19.8% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €8.82 Million | 29.7% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how ACELRX PHARMACEUT. DL-01's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see R5XA company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ACELRX PHARMACEUT. DL-01's current assets represent 70.3% of total assets in 2025, an increase from 64.8% in 2021.
- Cash Position: Cash and equivalents constituted 19.8% of total assets in 2025, up from 9.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 29.7% of total assets.
ACELRX PHARMACEUT. DL-01 Competitors by Total Assets
Key competitors of ACELRX PHARMACEUT. DL-01 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $36.83 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
ACELRX PHARMACEUT. DL-01 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.49 | 3.56 | 4.42 |
| Quick Ratio | 5.49 | 3.56 | 4.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €17.09 Million | €6.77 Million | €9.43 Million |
ACELRX PHARMACEUT. DL-01 - Advanced Valuation Insights
This section examines the relationship between ACELRX PHARMACEUT. DL-01's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.63 |
| Latest Market Cap to Assets Ratio | 1.31 |
| Asset Growth Rate (YoY) | 63.0% |
| Total Assets | €29.72 Million |
| Market Capitalization | $38.92 Million USD |
Valuation Analysis
Above Book Valuation: The market values ACELRX PHARMACEUT. DL-01's assets above their book value (1.31x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: ACELRX PHARMACEUT. DL-01's assets grew by 63.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ACELRX PHARMACEUT. DL-01 (2021–2025)
The table below shows the annual total assets of ACELRX PHARMACEUT. DL-01 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €29.72 Million ≈ $34.74 Million |
+62.97% |
| 2024-12-31 | €18.24 Million ≈ $21.32 Million |
-10.59% |
| 2023-12-31 | €20.39 Million ≈ $23.84 Million |
-57.05% |
| 2022-12-31 | €47.49 Million ≈ $55.52 Million |
-39.04% |
| 2021-12-31 | €77.89 Million ≈ $91.07 Million |
-- |
About ACELRX PHARMACEUT. DL-01
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more